Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
This predictive technology empowers people with diabetes to take preventive action before complications arise
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The inspection concluded with zero form 483 observations
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Encouraging early detection and breaking the silence around men’s health
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Subscribe To Our Newsletter & Stay Updated